^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

loperamide

i
Other names: JNJ-289679
Associations
Company:
Generic mfg.
Drug class:
µ-opioid agonist
Related drugs:
Associations
15d
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial. (PubMed, Br J Cancer)
The triple combination showed moderate tolerability and termination occurred after the first stage of Phase II due to insufficient efficacy. Our findings highlight challenges in translating organoid-derived drug combinations to clinical practice.
P1/2 data • Journal
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
lapatinib • Mektovi (binimetinib) • vinorelbine tartrate • loperamide
22d
Acacetin Alleviates Loperamide-Induced Functional Constipation by Inhibiting P53-Mediated Apoptosis in Colonic Epithelial Cells. (PubMed, Neurogastroenterol Motil)
Acacetin alleviates loperamide-induced FC by inhibiting P53-mediated apoptosis in colonic epithelial cells, providing new insights into the therapeutic mechanisms of traditional Chinese herbal medicine YWL in treating constipation.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
loperamide
23d
Multi-System Analysis of Opioid Receptor Binding (clinicaltrials.gov)
P1, N=25, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=60 --> 25 | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
loperamide
1m
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients (clinicaltrials.gov)
P1, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
loperamide
1m
Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study. (PubMed, Clin Transl Oncol)
Episodes of diarrhea were mostly graded 1-2 and no patients discontinued abemaciclib due to diarrhea. Patients reported high satisfaction with abemaciclib PSP, good adherence, and favorable quality of life, supporting the use of PSP in clinical practice.
Observational data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • EGFR positive
|
Verzenio (abemaciclib) • loperamide
2ms
New P2 trial
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
fulvestrant • Truqap (capivasertib) • loperamide
2ms
New P2/3 trial
|
loperamide
2ms
nextMONARCH 1: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=234, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
tamoxifen • Verzenio (abemaciclib) • loperamide
3ms
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov)
P2, N=34, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion
|
sunitinib • Recentin (cediranib) • Leukine (sargramostim) • Neupogen (filgrastim) • loperamide
3ms
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov)
P1, N=198, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
|
HR positive • HER-2 negative • EGFR positive
|
Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide
3ms
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
P1, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Jul 2028
Trial completion date
|
temozolomide • Xpovio (selinexor) • loperamide
3ms
The improvement effect and mechanism of traditional Chinese medicine on chemotherapy-induced diarrhea: a systematic review. (PubMed, Front Pharmacol)
The medications commonly used to improve CID include loperamide and octreotide...We found that TCM has a definite therapeutic effect in the treatment of CID, which reflected in multiple levels and multiple pathways, including Keap1/Nrf2, TLR4/NLRP3, TLR4/NF-κB, JAK2/STAT3, Wnt, AKT, and MAPK. The aim of this review was to provide some references for applying TCM to treat CID in clinic, and provide new insights into the critical path ahead of the development of innovative drugs in alleviating CID.
Review • Journal
|
JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TLR4 (Toll Like Receptor 4) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
loperamide